# A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)

> **NCT04660539** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 119 (actual)

## Conditions studied

- Neuromyelitis Optica Spectrum Disorder

## Interventions

- **DRUG:** satralizumab
- **DRUG:** azathioprine (AZA)
- **DRUG:** mycophenolate mofetil (MMF)
- **DRUG:** oral corticosteroids

## Key facts

- **NCT ID:** NCT04660539
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-02
- **Primary completion:** 2024-05-28
- **Final completion:** 2024-05-28
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04660539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04660539, "A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT04660539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*